GlassScriptPhysician profile
None Vimal Ravi
NPI 1578996419
$3,626.32
in general payments reported to CMS, 2019-2025
31 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $41.81 · 2022: $123 · 2023: $548 · 2024: $1,970 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608 · Education: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.07 |
| Education | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,673.54 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $452.60 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.91 | 2019-2025 | Ofev |
| Grifols USA, LLC | $129.47 | 2022-2025 | Prolastin-C Liquid, Xembify |
| United Therapeutics Corporation | $113.36 | 2023-2025 | Tyvaso |
| Abbvie INC. | $102.28 | 2022-2024 | Avycaz |
| Merck Sharp & Dohme LLC | $92.67 | 2023-2025 | Zerbaxa, Recarbrio |
| Mylan Specialty L.P. | $85.74 | 2019-2024 | Yupelri |
| Glaxosmithkline, LLC. | $72.58 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $67.58 | 2019-2025 | Dupixent |
| Baxter Healthcare | $65.50 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $63.65 | 2019-2025 | Xolair |
| Viatris Specialty LLC | $51.00 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $47.44 | 2023-2024 | |
| Amgen INC. | $46.00 | 2024-2025 | Tezspire |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $40.42 | 2019-2023 | Opsumit, Uptravi |
| Jazz Pharmaceuticals INC. | $40.04 | 2024-2025 | |
| Genzyme Corporation | $39.16 | 2025 | |
| Ani Pharmaceuticals, INC. | $37.83 | 2022-2024 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $31.86 | 2025 | Ohtuvayre |
| Circassia INC. | $30.49 | 2019 | |
| Electromed, INC. | $29.76 | 2025 | Smartvest |
| Ambu INC. | $29.69 | 2023 | |
| Idorsia Pharmaceuticals US INC | $28.49 | 2023-2024 | Quviviq |
| Insmed, INC. | $23.29 | 2024 | Arikayce |
| Axsome Therapeutics, INC. | $20.33 | 2025 | Sunosi |
| Philips North America LLC | $18.33 | 2023 | |
| Mallinckrodt Hospital Products INC. | $16.29 | 2023 | Acthar |
| Pulmonx Corporation | $13.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.55 | 2022 | |
| Pfizer INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw None Vimal Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.